Stockscreener 앱 받기
6.16
3.53%
0.21
시간 외 거래:
6.40
0.24
+3.90%
전일 마감가:
$5.95
열려 있는:
$5.89
하루 거래량:
1.42M
Relative Volume:
0.96
시가총액:
$546.98M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-2.3784
EPS:
-2.59
순현금흐름:
$-134.39M
1주 성능:
+0.65%
1개월 성능:
-21.13%
6개월 성능:
+4.94%
1년 성능:
-57.28%
1일 변동 폭
$5.57
$6.22
1주일 범위
$5.57
$6.81
52주 변동 폭
$4.305
$14.57
Verve Therapeutics Inc Stock (VERV) Company Profile
명칭
Verve Therapeutics Inc
전화
(978) 501-3026
주소
201 BROOKLINE AVENUE, BOSTON
VERV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
6.16 | 546.98M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-10-06 | 개시 | Credit Suisse | Neutral |
| 2022-08-25 | 업그레이드 | Stifel | Hold → Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-07-12 | 개시 | Guggenheim | Buy |
| 2021-07-12 | 개시 | JP Morgan | Neutral |
| 2021-07-12 | 개시 | Jefferies | Buy |
| 2021-07-12 | 개시 | William Blair | Outperform |
모두보기
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
(VERV) Technical Data - Stock Traders Daily
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World
Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada - Defense World
Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks
RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Analysts Set Expectations for VERV Q1 Earnings - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights
Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks
Vertex ends gene editing research pact with Verve - BioPharma Dive
Verve Therapeutics, Inc. SEC 10-K Report - TradingView
Verve Therapeutics: Q4 Earnings Snapshot -February 27, 2025 at 07:33 am EST - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Verve's Gene Editing Trials Deliver? Key PCSK9 Data Coming in 2025 With $524M War Chest - StockTitan
VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How To Trade (VERV) - Stock Traders Daily
William Blair Reaffirms Outperform Rating for Verve Therapeutics (NASDAQ:VERV) - Defense World
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday - Defense World
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Shareholders that Lost Money on Verve Therapeutics, Inc. (VERV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships - TipRanks
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships - TipRanks
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Verve Therapeutics, Inc. (VERV) Investigation - ACCESS Newswire
Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 10.4% HigherShould You Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Down 4.9%Time to Sell? - MarketBeat
Verve Therapeutics Inc (VERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):